[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,013
Citations 0
Comment & Response
March 10, 2015

Preventing Prescription Opioid Abuse

Author Affiliations
  • 1Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA. 2015;313(10):1059-1060. doi:10.1001/jama.2015.0518

To the Editor Although Dr Jones and colleagues1 claimed that the FDA regards “Preventing prescription opioid deaths [as] a public health priority,” this is not consistent with the FDA’s behavior. For example, the FDA instituted the untested, class-wide Risk Evaluation and Mitigation Strategy (REMS) program but continued to approve new extended release/long-acting (ER/LA) opioids with no evidence that the REMS actually reduces ER/LA opioid-related morbidity.